This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Hypericin
- DrugBank Accession Number
- DB13014
- Background
Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Hypericin (DB13014)
- Weight
- Average: 504.4432
Monoisotopic: 504.084517488 - Chemical Formula
- C30H16O8
- Synonyms
- Hipericina
- Hypericin
- Hypéricine
- Hypericum red
- Hyperizin
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UGlutathione S-transferase A1 Not Available Humans UGlutathione S-transferase P inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Hypericin. Abatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Hypericin. Acenocoumarol The risk or severity of adverse effects can be increased when Hypericin is combined with Acenocoumarol. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Hypericin. Acetophenazine The risk or severity of adverse effects can be increased when Acetophenazine is combined with Hypericin. Aclidinium Hypericin may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Hypericin. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Hypericin. Agomelatine The risk or severity of adverse effects can be increased when Agomelatine is combined with Hypericin. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hypericin. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzopyrenes. These are organic compounds containing a benzene fused to a pyrene(benzo[def]phenanthrene) ring system.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Pyrenes
- Sub Class
- Benzopyrenes
- Direct Parent
- Benzopyrenes
- Alternative Parents
- Phenanthro-perylenequinones / Triphenylenes / Chrysenes / Phenanthrols / Anthracenes / Naphthols and derivatives / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Polyols / Organic oxides show 1 more
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / 1-naphthol / 2-naphthol / Anthracene / Aromatic homopolycyclic compound / Benzo-a-pyrene / Benzo-e-pyrene / Chrysene / Hydrocarbon derivative / Organic oxide show 9 more
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- carbopolycyclic compound (CHEBI:5835) / Anthracenes and phenanthrenes, Anthrone type (C07606) / Anthracenes and phenanthrenes (LMPK13040001)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 7V2F1075HD
- CAS number
- 548-04-9
- InChI Key
- BTXNYTINYBABQR-UHFFFAOYSA-N
- InChI
- InChI=1S/C30H16O8/c1-7-3-9(31)19-23-15(7)16-8(2)4-10(32)20-24(16)28-26-18(12(34)6-14(36)22(26)30(20)38)17-11(33)5-13(35)21(29(19)37)25(17)27(23)28/h3-6,31-36H,1-2H3
- IUPAC Name
- 5,7,11,18,22,24-hexahydroxy-13,16-dimethyloctacyclo[13.11.1.1^{2,10}.0^{3,8}.0^{4,25}.0^{19,27}.0^{21,26}.0^{14,28}]octacosa-1(27),2(28),3,5,7,10,12,14,16,18,21,23,25-tridecaene-9,20-dione
- SMILES
- CC1=C2C3=C(C)C=C(O)C4=C3C3=C5C2=C(C(O)=C1)C(=O)C1=C5C(=C(O)C=C1O)C1=C(O)C=C(O)C(C4=O)=C31
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0034271
- KEGG Compound
- C07606
- PubChem Compound
- 5281051
- PubChem Substance
- 347829150
- ChemSpider
- 4444511
- BindingDB
- 50060874
- 1546455
- ChEBI
- 5835
- ChEMBL
- CHEMBL286494
- ZINC
- ZINC000003780340
- Wikipedia
- Hypericin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Cutaneous T Cell Lymphomas (CTCL) 1 2 Active Not Recruiting Other Cutaneous T-Cell Lymphoma/Mycosis Fungoides 1 2 Not Yet Recruiting Treatment Psoriasis (PsO) / Psoriasis Vulgaris (Plaque Psoriasis) 1 1 Completed Treatment Human Immunodeficiency Virus (HIV) Infections 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00732 mg/mL ALOGPS logP 3.92 ALOGPS logP 7.7 ChemAxon logS -4.8 ALOGPS pKa (Strongest Acidic) 6.03 ChemAxon pKa (Strongest Basic) -1.2 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 8 ChemAxon Hydrogen Donor Count 6 ChemAxon Polar Surface Area 155.52 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 139.31 m3·mol-1 ChemAxon Polarizability 50.98 Å3 ChemAxon Number of Rings 8 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available MS/MS Spectrum - , negative LC-MS/MS splash10-0udi-0000090000-e9cd20b64eba34b7fb1e MS/MS Spectrum - , positive LC-MS/MS splash10-0a4i-0000590000-d6f4544a5f160b2a5b67
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Glutathione transferase activity
- Specific Function
- Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
- Gene Name
- GSTA1
- Uniprot ID
- P08263
- Uniprot Name
- Glutathione S-transferase A1
- Molecular Weight
- 25630.785 Da
References
- Lu WD, Atkins WM: A novel antioxidant role for ligandin behavior of glutathione S-transferases: attenuation of the photodynamic effects of hypericin. Biochemistry. 2004 Oct 12;43(40):12761-9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- S-nitrosoglutathione binding
- Specific Function
- Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
- Gene Name
- GSTP1
- Uniprot ID
- P09211
- Uniprot Name
- Glutathione S-transferase P
- Molecular Weight
- 23355.625 Da
References
- Lu WD, Atkins WM: A novel antioxidant role for ligandin behavior of glutathione S-transferases: attenuation of the photodynamic effects of hypericin. Biochemistry. 2004 Oct 12;43(40):12761-9. [Article]
- Dalmizrak O, Kulaksiz-Erkmen G, Ozer N: Evaluation of the in vitro inhibitory impact of hypericin on placental glutathione S-transferase pi. Protein J. 2012 Oct;31(7):544-9. doi: 10.1007/s10930-012-9433-6. [Article]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Lu WD, Atkins WM: A novel antioxidant role for ligandin behavior of glutathione S-transferases: attenuation of the photodynamic effects of hypericin. Biochemistry. 2004 Oct 12;43(40):12761-9. [Article]
Drug created at October 21, 2016 02:05 / Updated at May 05, 2022 15:33